Validation of imatinib therapy failure score (IMTF) in chronic phase chronic myeloid leukemia in real life practice

Claudia IeloDepartment of Translational and Precision Medicine, Az. Policlinico Umberto I-Sapienza University, Rome, ItalyView further author information

Emilia ScalzulliDepartment of Translational and Precision Medicine, Az. Policlinico Umberto I-Sapienza University, Rome, ItalyView further author information

Ida CarmosinoDepartment of Translational and Precision Medicine, Az. Policlinico Umberto I-Sapienza University, Rome, ItalyView further author information

Sara PepeDepartment of Translational and Precision Medicine, Az. Policlinico Umberto I-Sapienza University, Rome, ItalyView further author information

Maria Laura BisegnaDepartment of Translational and Precision Medicine, Az. Policlinico Umberto I-Sapienza University, Rome, ItalyView further author information

Maurizio MartelliDepartment of Translational and Precision Medicine, Az. Policlinico Umberto I-Sapienza University, Rome, ItalyView further author information

Massimo BrecciaDepartment of Translational and Precision Medicine, Az. Policlinico Umberto I-Sapienza University, Rome, ItalyCorrespondence[email protected]
View further author information

show all

References

Hochhaus A, Larson RA, Guilhot F, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376(10):917–927. doi:10.1056/NEJMoa1609324
PubMed Web of Science ®Google Scholar
Pfirrmann M, Clark RE, Prejzner W, et al. The EUTOS long-term survival (ELTS) score is superior to the sokal score for predicting survival in chronic myeloid leukemia. Leukemia. 2020;34(8):2138–2149. doi:10.1038/s41375-020-0931-9
PubMed Web of Science ®Google Scholar
Zhang XS, Gale RP, Zhang MJ, et al. A predictive scoring system for therapy-failure in persons with chronic myeloid leukemia receiving initial imatinib therapy. Leukemia. 2022;36(5):1336–1342. doi:10.1038/s41375-022-01527-y
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Validation of imatinib therapy failure score (IMTF) in chronic phase chronic myeloid leukemia in real life practice

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Validation of imatinib therapy failure score (IMTF) in chronic phase chronic myeloid leukemia in real life practice

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date